Search the Newsreel

Moderna (MRNA) Projected to Post Earnings on Friday

Moderna (MRNA) is projected to announce its Q2 2026 earnings before the market opens on Friday, July 31st. Analysts expect a loss of ($2.00) per share on revenue of approximately $103.1 million. The company's prior quarter widely beat revenue estimates but still posted a …

Earnings Preview: What To Expect From Moderna’s Report

Himension Capital Singapore PTE. LTD. Cuts Position in Moderna, Inc. $MRNA

Himension Capital Singapore PTE. LTD. reduced its stake in Moderna, Inc. by 38.8% in Q1, selling 22,390 shares and holding stock worth $1.795 million. Despite this, other institutions like PNC Financial Services Group Inc., Commerzbank Aktiengesellschaft FI, AlTi Global Inc., Meeder Advisory Services Inc., …

Moderna Rabies Vaccine Candidate by Moderna Inc. - mRNA approach in early trials

Moderna Inc. is developing an mRNA-based rabies vaccine candidate, which is currently in early clinical development as a prophylactic. This vaccine uses mRNA technology to trigger an immune response against the rabies virus, potentially offering a more flexible and faster development process compared to …

California Public Employees Retirement System Purchases 149,192 Shares of Moderna, Inc. $MRNA

The California Public Employees Retirement System increased its stake in Moderna, Inc. by 31.1% in the first quarter, purchasing an additional 149,192 shares. Other institutional investors also adjusted their holdings in Moderna, which currently has 75.33% institutional ownership. Analyst ratings for Moderna are mixed, …

Is Moderna (MRNA) Fully Valued As Board Changes And Earnings Near?

Moderna (MRNA) has appointed Michael McDonnell to its Board and Audit Committee amidst fluctuating stock performance and an upcoming earnings report. While the company has seen strong year-to-date gains, its valuation is considered overvalued by analysts, with a consensus price target of $44.25 against …

Moderna (MRNA) Appoints Michael McDonnell To Board As Committee Roles Shift

Moderna has appointed Michael McDonnell to its Board of Directors and Audit Committee, a move aimed at strengthening financial oversight for the company. McDonnell's extensive background in life sciences and as a public company CFO is expected to influence Moderna's approach to capital allocation, …

Moderna Inc. Stock Slides 3.8%, Underperforms Peers

Moderna Inc. (MRNA) saw its stock price decline by 3.8%. This performance indicates that Moderna underperformed compared to its peers within the market. The article provides a brief overview of this stock movement.

Moderna Is Up 109% in 2026. Jim Cramer Just Called It 'Finally Investable Again.' Is the Stock a No-Brainer Buy on Its Recent Pullback?

Moderna's stock has surged 109% in 2026, leading Jim Cramer to declare it "finally investable again." Despite past disappointments and declining coronavirus vaccine demand, the company has made significant progress in its pipeline, cost-cutting, and currently has three approved products, with a flu vaccine …

Goldman Sachs Adjusts Moderna Price Target to $67 From $49, Maintains Neutral Rating

Goldman Sachs has raised its price target for Moderna (MRNA) to $67 from $49, while keeping a Neutral rating on the stock. This adjustment comes amidst various company developments, including Moderna advancing its cancer therapy assessment and recent patent infringement suits against competitors Pfizer …

MRNA Advances Cancer Pipeline With New Immunotherapy Study

Moderna (MRNA) has initiated a phase I study for mRNA-4200, an investigational off-the-shelf, tumor-targeted cancer antigen therapy, in patients with advanced solid tumors. This move aligns with Moderna's long-term strategy to diversify its mRNA platform beyond vaccines into oncology, developing cancer antigen therapies in …

MRNA: Moderna Inc Latest Stock Price, Analysis, News and Trading Ideas

This page provides current stock information for Moderna Inc. (MRNA), including its latest stock price, market capitalization, volume, 52-week high/low, and PE ratio. It also features recent news headlines related to Moderna and discussions about other trending stocks like SPY, SG, and NFLX.

Moderna (MRNA): Buy, Sell, or Hold Post Q1 Earnings?

Despite a 46.4% stock price jump for Moderna (MRNA) over the last six months, partly due to solid quarterly results, StockStory advises against buying the stock. This recommendation is based on a significant decline in revenue and EPS over the past five years, along …

Form 4 Moderna Inc For: 16 July By Investing.com

This article reports a Form 4 filing for Moderna Inc. on July 16, 2026. The piece is brief, stating the filing and including the stock symbol MRNA with a reported -7.51% change. It appears to be an automated news update.

Moderna president Stephen Hoge sells $3.6m in stock

Moderna President Stephen Hoge sold approximately $3.6 million worth of company stock on July 15, 2026, while also acquiring shares through stock options. The transactions were conducted under a Rule 10b5-1 trading plan. This sale occurred as Moderna's stock, MRNA, showed a 132% year-to-date …

Moderna, Inc. (MRNA) president exercises options and sells 53,336 shares under 10b5-1 plan

Moderna President Stephen Hoge exercised stock options to acquire 53,336 shares of common stock at $19.15 per share and subsequently sold all 53,336 shares at $67.60 per share. These transactions, executed on July 15, 2026, were conducted under a pre-arranged Rule 10b5-1 trading plan …

Moderna Inc (MRNA) weekly reversal tests a biotech rebound

The pullback matters because longer weekly returns remain positive, leaving the setup supported but no longer one-way.

ABUS Stock On Track For Best Day In About Two Months — What’s The Moderna Connection?

Arbutus Biopharma (ABUS) stock rose 6% after the company announced new international patent lawsuits, received a significant settlement payment from Moderna, and revealed plans to return up to $230 million to shareholders through share repurchases. The company received approximately $178 million from Moderna as …

Moderna doses first patient in cancer therapy trial

Moderna has initiated a Phase 1 study by dosing the first U.S. patient with mRNA-4200, an investigational cancer therapy for advanced or metastatic solid tumors. This therapy, developed in collaboration with Immatics, encodes seven common cancer antigens and will be evaluated for safety and …

Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors

Moderna has announced that the first participant has been dosed in its Phase 1 clinical trial for mRNA-4200, an investigational tumor-targeted cancer antigen therapy. This therapy aims to induce and expand T-cell responses against multiple shared tumor targets in patients with advanced or metastatic …

Moderna Trial Tests Cancer Therapy Encoding Seven Antigens

Moderna has announced that the first U.S. participant has been dosed in its Phase 1 clinical trial for mRNA-4200, an investigational tumor-targeted cancer antigen therapy. This therapy, designed to stimulate T-cell responses against seven shared tumor targets, aims to treat advanced or metastatic solid …

YieldMax MRNA option income strategy ETF declares $0.3647 dividend

The YieldMax MRNA Option Income Strategy ETF has declared a monthly dividend of $0.3647 per share. This announcement highlights its income strategy as an exchange-traded fund.

Sanofi sues Pfizer, Moderna over COVID shot technology

Sanofi has filed lawsuits against Pfizer and Moderna, alleging that their COVID-19 vaccines infringe on multiple patents held by the French pharmaceutical company. The lawsuits claim that the mRNA innovations used in Pfizer and Moderna's blockbuster vaccines violate Sanofi's patent rights, specifically those covering …

Sanofi Sues Moderna, Pfizer for Vaccine-Tech Patent Royalties

Sanofi has filed federal lawsuits against Moderna and Pfizer, seeking patent royalties for their COVID-19 and RSV vaccines. Sanofi alleges that Moderna's Spikevax, mNexspike, and mResvia vaccines, and Pfizer's Comirnaty vaccine, infringe upon as many as 10 mRNA delivery patents held by Sanofi's unit, …

Moderna (NASDAQ: MRNA) holder Stephen Hoge plans 53,336-share sale

Stephen Hoge, a holder of Moderna (NASDAQ: MRNA) stock, has filed a notice for a proposed sale of up to 53,336 common shares. These shares are associated with a stock option exercise dated July 15, 2026, and the sale will be conducted through Fidelity …

Moderna Inc (MRNA) gives back 14.4% despite 36.8% four-week gain

The biotech stock’s weekly reversal complicates a broader rebound, with turnover still above recent norms.

Moderna Inc (MRNA) momentum broadens with 68.1% four-week surge

The biotechnology stock’s latest weekly close extends a sharp rebound, with strength readings firm but volume evidence not entirely uniform.

Moderna Inc (MRNA) four-week rebound reaches 42.6%

The biotechnology stock’s weekly setup remains active, with momentum readings positive but Market Dynamics confirmation still modest.

Moderna Inc (MRNA) extends rebound as four-week gain reaches 42.6%

The biotechnology stock’s weekly setup has improved, but volume evidence leaves confirmation mixed.

Moderna Inc (MRNA) rebounds 28.2% as weekly trading volume jumps

The biotech stock’s recovery has widened beyond the latest week, though pressure readings keep the signal mix from looking clean.

Moderna Inc (MRNA) jumps 28.2% in a heavy-volume weekly move

The biotechnology stock’s rebound has broadened over the past month, but Market Dynamics still points to pressure rather than clean confirmation.

Moderna Inc (MRNA) moves back into focus on heavy weekly trading

The biotech rebound now spans multiple weekly windows, but momentum confirmation remains uneven.

Moderna’s 28% week leads Healthcare on heavier volume, with pressure still unconvinced

MRNA closed at 63.96 after a sharp weekly advance, ranking first in US Healthcare and US Biotechnology, but the Sharemaestro read remains balanced as activity pressure stays negative.

Moderna Inc (MRNA) turnover jumps as four-week rebound reaches 36.4%

The biotechnology stock is back on the active-mover screen, but momentum evidence is not all one-way.

Moderna's Revenues See Strong International Momentum in Q1 Earnings

Moderna (MRNA) Q1 2026 Earnings Transcript